ArticleNature2025
CD45-PET is a robust, non-invasive tool for imaging inflammation.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Site-Specific Labeling of PD-L1 Fab through Disulfide Rebridging for ImmunoPET Imaging.Chemical & biomedical imaging · 2026Article
- Article
- Ultrasensitive detection of lung inflammation in male mice using immuno-magnetic particle imaging.Nature communications · 2026Article
- Immuno-positron emission tomography in cardiovascular disease: Advances, challenges, and opportunities.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026Review
- Suppression of Ciliogenesis Alleviates Cellular Senescence via AKT Signaling in Gingival Aging.Aging cell · 2026Article
- CD45 as a multifunctional target in immune regulation and therapeutic delivery.Journal of translational medicine · 2026Review
- Molecular imaging of immune and fibrosis targets to guide therapy for repair after myocardial infarction.Nature reviews. Cardiology · 2026Review
- Host-Pathogen Interactions Leading to Pneumonia Pathogenesis.Clinics in chest medicine · 2026Review
- Clinical applications of PET imaging for evaluating treatment-induced vascular toxicity in oncology.Current opinion in hematology · 2026Review
- Infiltrative and Inflammatory Cardiomyopathies: Using Imaging to Probe Mechanisms of Myocardial Dysfunction.Journal of cardiac failure · 2026Review
- Organotellurium Probes Enable One-step Single-cell Analysis of Post-translational Modification.Journal of the American Chemical Society · 2026Article
- Nanoparticle retention enables non-invasive detection of metastases by magnetic particle imaging in murine breast cancer models.Theranostics · 2026Article
- Molecular contrast agents for post-infarct cardiac remodelling: a contemporary review.European heart journal. Imaging methods and practice · 2026Review
- Can Nuclear Imaging Detect Trained Immunity in Cardiovascular Disease?Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- A NovelPharmaceutics · 2025Article
- CD45-targeted pan-leukocyte imaging: mapping whole-body inflammatory activity with specificity and translational promise.Signal transduction and targeted therapy · 2025Article
- Activatable companion theranostics for dual-modality imaging-escorted pyroptosis-propelled synergistic cancer therapy.Bioactive materials · 2025Article
- Molecular tools for decoding multicellular systems: from mechanisms to medicine.National science review · 2025Review
- Pulmonary Biomechanics in COPD: Imaging Techniques and Clinical Applications.Journal of biomechanical engineering · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Ali Salehi Farid *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-3135-1076
Jennifer E Rowley *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9178-1719
Harris H AllenDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0001-4800-4700
Isabella G KrugerDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Soheil TavakolpourDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kyle NeeleyDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0007-7749-0473
Min CongDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Haneyeh ShahbazianDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Niki DorafshaniDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Achraf BerradaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander C MacDonaghDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0009-0009-1821-6268
Robert F PaderaHarvard Medical School, Boston, MA, USA.
Pedro BrugarolasHarvard Medical School, Boston, MA, USA.
Alan B PackardHarvard Medical School, Boston, MA, USA.
Matthew W RosenbaumHarvard Medical School, Boston, MA, USA.
Sanjay DivakaranHarvard Medical School, Boston, MA, USA.
Marcelo F Di CarliHarvard Medical School, Boston, MA, USA.
Mohammad RashidianDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. mohammad_rashidian@dfci.harvard.edu.ORCID 0000-0002-3708-0038
Funding
Non-invasive imaging of the anti-tumor immune responseR01CA255216 · NCI · BOSTON CHILDREN'S HOSPITAL · PI PISHESHA, NOVALIA · 2021 to 2025
$2.9MDeveloping non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseasesR01AI165666 · NIAID · DANA-FARBER CANCER INST · PI Mohammad Rashidian, Erin wei · 2023 to 2026
$2.7MNoninvasive monitoring and evaluation of anti-tumor responses as a predictive toolK22CA226040 · NCI · DANA-FARBER CANCER INST · PI RASHIDIAN, MOHAMMAD · 2019 to 2021
$574kNCI NIH HHS K22 CA226040NCI NIH HHS R01 CA255216NIAID NIH HHS R01 AI165666
Abstract
Imaging inflammation holds immense potential for advancing the diagnosis, treatment and prognosis of many conditions
Indexed as
InflammationLeukocyte Common AntigensPositron-Emission TomographyAnimalsDisease Models, AnimalFemaleFluorodeoxyglucose F18HumansInflammatory Bowel DiseasesMaleMiceFluorodeoxyglucose F18Leukocyte Common AntigensPTPRC protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.